Summary Pages 4 and 5 Interview Zoltan Csizer, UNIDO Director of Cleaner Production and Enviromental Managment Branch New tablets plant - a modern world class quality pharmaceutical plant A<strong>dd</strong>itional funds for this type of project have, as you know, been provided thanks to extremley high engagment of the company’s top managment. You are following its implementation. Are you satisfied? You have proably seen the Injectables Plant too. We shall appreciate to hear your assessment for both? I have seen the Injectables Plants when it was in less advanced construc- Page 6 A heavy task R & D is successfully reaching the strategic goal of bosnalijek In recent years, through introduction of the whole range of new drugs in production, <strong>Bosnalijek</strong> is realizing its strategic goal: expand its products range and meeting about 60% of B-H populations demands, thus Page 9 Partnership * foreign contacts Eli Lilly Mi<strong>dd</strong>le of Marchthis year <strong>Bosnalijek</strong> has concluded two extraordinary significant business arrangements with American company Eli Lilly, the following statements were released: Edin Arslanagi}, General Manager of <strong>Bosnalijek</strong>: - I must express my satisfaction that after 8 month of negotiations, we managed to execute this agreement tion stage than the Tablets Plant is Today. I am telling this based on a very short visit where I was polite enough not to put many questions. I would say that it is extremley difficult to create something new wich meets the international standards in an building structure. The other facility, the Tablets Production Plant is different. First, that was a larger building and as we saw from the video it was scaled dowwn up to the skeleton of the building and everything is quite brand new now. That almost a green field new construction. And of course, what I have seen I like very much. That will be a modern, world class quality, new pharmaceutical plant. How do you see <strong>Bosnalijek</strong> tomorrow, do you hav some suggestion in that respect? I don’t want to encourage or discourage anybody, but the future of <strong>Bosnalijek</strong> is not going to be easy. I personally belive that the very capable making <strong>Bosnalijek</strong> the leading drug supplier of this market. Great contribution here was given by R & D Division which, in accordance with very strict international standards of development, its testing and introducing drugs in production in form of tablets, capsules,syrups, suspensions, ointaments, creams, jellies, injections solutions, etc. Implementation of a new drug development is running in specilized laboratories: which will result in our better bids. It will be just that what this market was missing. I am particulary pointing out to human insulins. Our goal is, as known, to make <strong>Bosnalijek</strong> leader in supplying Bosna-Hercegovina market with drugs. In this way the goal will be easier of attainment. The agreement is made for 5 years period and will encompass 33 new drugs of very good quality, thus expanding our product range by 20%. I think that it is only the first phase of our cooperation. In fact, I am expecting <strong>Bosnalijek</strong> and Eli Lilly to find out managment of <strong>Bosnalijek</strong> knows that well. But what I have seen in the last couple of years, and I became almost friend to many of the high managers of the company, that after long they bring very wise and smart decision. One of the most important decisions was not to move back for chemical synthesis. And we should face the fact that for time being <strong>Bosnalijek</strong> is small company and realistic target of a small company can be and shall be only to make that part of production which has the highest profit. As for the future decisions, I would like to advise you that as long as the country has get the priorites through the law you should go for some modern generics formulations wich are just out from the patent protection. With this approach you will have success and make a very important to get some sort of cooperation with some other companies in the outside world. And up to now <strong>Bosnalijek</strong> has already made this type of effort, among other - pharmaceutical technology laoratories - analytic laboratory - stability tests laoratory Contiuous training aboard (attending symposia, congresses, courses) exchange of professional information and experience with foreign partners (Lilly, novartis, Biochemie, API, IMP Fisiopharma, PHARCO,...). for the purpose of improvment of quality and introduction of new knowledge for the future programs, as well as advanced train- some other ways of their mutual performance in even better quality. Eberhard Ludewigs, General manager of Eli Lilly in charge of Hungary, Slovenia, Croatia an Bosnia- Hercegovina: - In countries in which we ha not een present so far we are searching for the best partners. Our products range covers five therapeutic areas: endocrinology, mainly with insulin products, then we have wide range of antibiotics for oral administration and in form of ampoules, products countries specifically with Slovenia. I know that a part of technological know-how for this new project is coming from LEK. And the last point whichI would like to emphasize and I know that the company did enough in this issue, is that the local market is so small that it would be so difficult to belive in the long run this company can function with such a small local market. i have heard that <strong>Bosnalijek</strong> is trying to make export to Ukraina, in fact there is interest there. Considering the political situation, I presume that Ukraina would not be too happy if they would need to buy all their drugs from Russia. That gives a good opportunity for the company. They will certanly be numerous. That should be dealt with, and you in <strong>Bosnalijek</strong> know how to proceed. Interviewers: A. Kapi} and B. Avdiegovi} ing through post-graduate studies and specialist training, is guaranty for realization of strategic goas of the company. This supported by the Expert Committee (composed of different profile experts), as well as Scientific Council composed of prominent professors in areas of medecine, pharmacy, chemistry. Midhat Vehabovi}, B. S. Pharm. Spec. for cardiovascular diseases, anticancer products as well as products for treatment of central nervous system diseases. These are treatment areas in the world in wich Eli Lillyhas advantage over other companies. All these areas, all these drugs, are covered by this agreement. Along with these activities, as said Mr. Arslanagi}, we shall be making plans for our mutual approach to the market. These activities will be coordinated in the best possible way.
Drugi o nama "Poslovne Novine " , mart/april 1998. "ONASA" , 23.07.1998.g. "Oslobo|enje" , petak, 13.03.1998.godine. "Zajednica" april, 1998.godine.
Change language